Our post-hoc analysis suggested that RZV is efficacious in preventing HZ irrespective of sex, geographic region and geographic ancestry/ethnicity.

Previous research suggests that women and individuals of European ancestry have an increased risk of getting shingles; however, our data did not show a difference in vaccine efficacy by sex.

The analysis shows that this vaccine appears highly efficacious against shingles in both women and men aged 50 years and older. Also, the level of protection appears independent of the participant’s ancestral heritage and of the geographic region where they resided.

While the risk of getting shingles has been shown to be increased among women and people of European descent, our results suggest that Shingrix prevents shingles irrespective of a person’s sex and geographic ancestry, or of their region of residence.